ANGIODYNAMICS INC 10-Q

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q. The following discussion should be read in conjunction with the Company's 2024 Annual Report on Form 10-K, and the consolidated financial statements and notes thereto included elsewhere in the Form 10-Q. Disclosure Regarding Forward-Looking Statements This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the Securities and Exchange Commission (the "SEC"). Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this report. AngioDynamics disclaims any obligation to update the forward-looking statements. Disclosure Regarding Trademarks This report includes trademarks, tradenames and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames. For a complete listing of all our trademarks, tradenames and service marks please visit www.angiodynamics.com/IP. Information on our website or connected to our website is not incorporated by reference into this Quarterly Report on Form 10-Q. Executive Overview AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use. Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, 24 Table of Content the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical devices; and fluctuations in the global economy. Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions of our product offerings are created through internal and external product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and selective business development opportunities to provide growth opportunities. We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of direct sales and distributor relationships. Our end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally. The current macroeconomic environment continues to impact our business and may continue to pose future risks. The Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog and inflation (including the cost and availability of raw materials, direct labor and shipping) have impacted our business, trends that may continue. Accordingly, management continues to evaluate the Company’s liquidity position, communicate with and monitor the actions of our customers and suppliers, and review our near-term financial performance. On January 5, 2024, the Company announced a restructuring of its manufacturing footprint and a shift to an outsourced model (the "Plan"). This Plan will transfer all product manufacturing processes to third-party manufacturers. In the second quarter of fiscal year 2025, the Company announced a modification to the Plan to maintain a presence in Queensbury, NY for the manufacturing of select products, customer service, logistics, shipping, quality and regulatory operations. The restructuring activities associated with the modified Plan are still expected to be completed in the third quarter of fiscal year 2026. The modified Plan is still expected to generate $15.0 million in annual cost savings starting in fiscal year 2027. On July 16, 2024, the Board of Directors approved a share repurchase program (the "Repurchase Program") under which they authorized the Company the option to repurchase up to $15.0 million of its outstanding common stock. The timing and amount of any share repurchases under the authorization will be determined by management within certain parameters and based on market conditions and other considerations. There were no share repurchases during the third quarter of fiscal year 2025. During the first quarter of fiscal year 2025, the Company repurchased 72,141 shares of common stock in the open market at an aggregate cost of $0.5 million under the Repurchase Program. During the second quarter of fiscal year 2025, the Company repurchased 171,706 shares of common stock in the open market at an aggregate cost of $1.1 million under the Repurchase Program. As of February 28, 2025, $13.3 million remained available for repurchase under the Repurchase Program. On December 24, 2024, the Company entered into an agreement to sell the manufacturing facilities in Queensbury, NY and Glens Falls, NY for a purchase price of $5.5 million and $1.2 million, respectively, and net proceeds of $5.2 million and $1.1 million, respectively. The Company simultaneously entered into lease agreements with future lease payments of $4.6 million over seven years for the Queensbury, NY facility and $0.4 million over three years for the Glens Falls, NY facility. In evaluating the operating performance of our business, management focuses on company-wide and segment revenue and gross margin and company-wide operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024 are as follows: Three months ended February 28, 2025: • Revenue decreased by 4.2% to $72.0 million • Med Tech growth of 21.3% and Med Device declined by 17.6% • Gross profit increased 630 bps to 54.0% • Med Tech gross profit increased 110 bps to 62.5% and Med Device gross profit increased 690 bps to 47.4% • Net loss decreased by $183.3 million to $4.4 million • Loss per share decreased by $4.56 to $0.11 Nine months ended February 28, 2025: • Revenue decreased by 8.8% to $212.3 million • Med Tech growth of 17.9% and Med Device declined by 22.1% 25 Table of Content • Gross profit increased 450 bps to 54.4% • Med Tech gross profit increased 40 bps to 63.2% and Med Device gross profit increased 430 bps to 47.8% • Net loss decreased by $143.0 million to $27.9 million • Loss per share decreased by $3.58 to $0.68 • Cash used in operations decreased by $4.2 million to $28.9 million For the three and nine months ended February 28, 2025, the decrease in revenue is due to the divestiture of the PICCs, Midline, dialysis and BioSentry businesses, along with the discontinuation of the RadioFrequency Ablation and Syntrax product lines, the total of which impacted sales by $9.2 million and $33.5 million compared to the three and nine months ended February 29, 2024, respectively. Our Med Tech revenue, comprised of Auryon, the thrombus management platform and NanoKnife, grew 21.3% in the third quarter of fiscal year 2025. Our Med Device revenue declined by 17.6% in the third quarter of fiscal year 2025 driven mainly by the divestiture of the PICCs, Midlines, dialysis and BioSentry businesses along with the discontinuation of the RadioFrequency Ablation product lines. Results of Operations For the three months ended February 28, 2025, the Company reported net loss of $4.4 million, or diluted loss per share of $0.11, on net sales of $72.0 million, compared with a net loss of $187.7 million, or diluted loss per share of $4.67, on net sales of $75.2 million during the same quarter of the prior year. For the nine months ended February 28, 2025, the Company reported net loss of $27.9 million, or diluted loss per share of $0.68, on net sales of $212.3 million, compared with a net loss of $170.9 million, or diluted loss per share of $4.26, on net sales of $232.9 million during the same quarter of the prior year. Net sales - Net sales are derived from the sale of products and related freight charges, less discounts, rebates and returns. Three Months Ended Nine Months Ended (in thousands) Feb 28, 2025 Feb 29, 2024 $ Change Feb 28, 2025 Feb 29, 2024 $ Change Net Sales Med Tech $ 31,341 $ 25,844 $ 5,497 $ 90,863 $ 77,068 $ 13,795 Med Device 40,663 49,338 (8,675) 121,477 155,866 (34,389) Total $ 72,004 $ 75,182 $ (3,178) $ 212,340 $ 232,934 $ (20,594) Three Months Ended Nine Months Ended (in thousands) Feb 28, 2025 Feb 29, 2024 $ Change Feb 28, 2025 Feb 29, 2024 $ Change Net Sales United States $ 61,340 $ 62,342 $ (1,002) $ 183,499 $ 190,743 $ (7,244) International 10,664 12,840 (2,176) 28,841 42,191 (13,350) Total $ 72,004 $ 75,182 $ (3,178) $ 212,340 $ 232,934 $ (20,594) For the three months ended February 28, 2025, net sales decreased $3.2 million to $72.0 million compared to the three months ended February 29, 2024. For the nine months ended February 28, 2025, net sales decreased $20.6 million to $212.3 million compared to the nine months ended February 29, 2024. At February 28, 2025, the Company had a sales order backlog of $0.5 million. The Med Tec h segment net sales increased $5.5 million and $13.8 million fo r the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The change in sales for both periods was primarily driven by: • Increased Auryon sales of $2.0 million and $7.2 million compared to the same period in the prior year, respectively; • Decreased sales of Syntrax of $0.2 million and $0.4 million, respectively, due to the discontinuation of this product line as of February 29, 2024; • Increased sales of the thrombus management platform of $3.3 million and $6.8 million compared to the same period in the prior year, respectively. This was driven by an increase in AngioVac and AlphaVac sales of $3.1 million and $6.3 million compared to the same periods in the prior year, respectively, and an increase in thrombolytic sales of $0.2 million and $0.5 million compared to the same periods in the prior year, respectively; and • Increased NanoKnife sales of $0.3 million and $0.2 million compared to the same period in the prior year, respectively, which was driven by increased disposable sales offset by decreased capital sales. 26 Table of Content The Me d Device segment net sales decreased $8.7 million and $34.4 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The backlog, which primarily impacted sales of Core and Oncology products, was $0.5 million. The change in sales for the three months ended February 28, 2025 compared to the three months ended February 29, 2024, was primarily driven by: • Decreased sales of PICCs and Midline products of $8.6 million, which was due to the divestiture of these businesses on February 15, 2024; • Decreased sales of RadioFrequency Ablation of $0.4 million due to the discontinuation of this product line as of February 29, 2024; and • Increased sales of Core and Microwave products of $0.7 million and $0.4 million, respectively, which was partially offset by decreased sales of Venous, Ports and Oncology products of $0.2 million, $0.2 million and $0.3 million, respectively. The change in sales for the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024, was primarily driven by: • Decreased sales of PICCs and Midline products of $30.2 million, which was due to the divestiture of these businesses on February 15, 2024; • Decreased sales of dialysis and BioSentry products of $0.7 million, which was due to the divestiture of these businesses on June 8, 2023; • Decreased sales of RadioFrequency Ablation of $2.2 million due to the discontinuation of this product line as of February 29, 2024; and • Decreased sales of Microwave and Oncology products of $1.0 million and $0.6 million, respectively, which was partially offset by increased sales of Core and Ports of $0.3 million and $0.1 million, respectively. Gross Profit Three Months Ended Nine Months Ended (in thousands) Feb 28, 2025 Feb 29, 2024 $ Change Feb 28, 2025 Feb 29, 2024 $ Change Med Tech $ 19,588 $ 15,857 $ 3,731 $ 57,398 $ 48,400 $ 8,998 Gross profit % of sales 62.5 % 61.4 % 63.2 % 62.8 % Med Device $ 19,269 $ 20,004 $ (735) $ 58,089 $ 67,783 $ (9,694) Gross profit % of sales 47.4 % 40.5 % 47.8 % 43.5 % Total $ 38,857 $ 35,861 $ 2,996 $ 115,487 $ 116,183 $ (696) Gross profit % of sales 54.0 % 47.7 % 54.4 % 49.9 % Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization. Total Company gross profit increased by $3.0 million and decreased by $0.7 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • The divestiture of the PICCs, Midline, dialysis and BioSentry businesses and abandonment of the Syntrax and RF product lines contributed $2.2 million and $9.2 million of gross profit, respectively; • Sales volume, price and product mix, which positively impacted gross profit by $5.4 million and $12.9 million, respectively; • Other incentives and a prior year supplier recall, which positively impacted gross profit by $1.2 million and $1.4 million, respectively; • Production volume and other costs, which negatively impacted gross profit by $1.2 million and $2.7 million, respectively; 27 Table of Content • Inflationary costs on raw materials, labor shortages and freight costs, which positively impacted gross profit by $0.5 million for the three months ended February 28, 2025 and which negatively impacted gross profit by $1.0 million for the nine months ended February 28, 2025; and • Incremental depreciation and other expense on placement units of $0.7 million and $2.0 million, respectively. The Med Tech segment gross profit increased by $3.7 million and $9.0 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • The abandonment of the Syntrax product line impacted gross profit by $0.1 million and $0.2 million, respectively; • Sales volume, price and product mix, which positively impacted gross profit by $4.9 million and $12.6 million, respectively; • Production volume, which positively impacted gross profit by $0.1 million and $0.1 million, respectively; • Other incentives and costs, which negatively impacted gross profit by $0.7 million and $1.3 million, respectively; • Inflationary costs on raw materials, labor shortages and freight costs negatively impacted gross profit by $0.3 million for the nine months ended February 28, 2025; and • Incremental depreciation and other expense on placement units of $0.6 million and $1.9 million, respectively. The Med Device segment gross profit decreased by $0.7 million and $9.7 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • The divestiture of the PICCs, Midline, dialysis and BioSentry businesses and abandonment of the RF product line contributed $2.1 million and $9.1 million of gross profit, respectively; • Price and product mix, which positively impacted gross profit by $0.9 million and $2.4 million, respectively; • A prior year supplier recall, which positively impacted gross profit by $1.2 million and $1.4 million, respectively; • Sales volume, production volume and other incentives and costs, which negatively impacted gross profit by $1.1 million and $3.5 million, respectively; • Inflationary costs on raw materials, labor shortages and freight costs positively impacted gross profit by $0.5 million for the three months ended February 28, 2025 and negatively impacted gross profit by $0.7 million for the nine months ended February 28, 2025; and • Incremental depreciation and other expense on placement units of $0.1 million for the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. Operating Expenses and Other Income (Expense) Three Months Ended Nine Months Ended (in thousands) Feb 28, 2025 Feb 29, 2024 $ Change Feb 28, 2025 Feb 29, 2024 $ Change Research and development $ 6,913 $ 8,189 $ (1,276) $ 19,632 $ 24,788 $ (5,156) % of sales 9.6 % 10.9 % 9.2 % 10.6 % Selling and marketing $ 25,504 $ 25,405 $ 99 $ 76,698 $ 78,237 $ (1,539) % of sales 35.4 % 33.8 % 36.1 % 33.6 % General and administrative $ 10,490 $ 10,578 $ (88) $ 31,856 $ 30,723 $ 1,133 % of sales 14.6 % 14.1 % 15.0 % 13.2 % Research and development expense - Research and development (“R&D”) expense includes internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs. R&D expense decreased $1.3 million and $5.2 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • The timing of certain projects and clinical spend associated with the ongoing clinical trials, which decreased R&D expense by $1.6 million and $5.8 million, respectively; and • Compensation and benefits expenses, which increased $0.3 million and $0.5 million, respectively. Sales and marketing expense - Sales and marketing (“S&M”) expense consists primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. 28 Table of Content S&M expense increased $0.1 million and decreased $1.5 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • Compensation and benefits expense, which decreased by $0.1 million and $2.5 million, respectively; • Trade shows, subscriptions and other marketing expenses, which increased $0.1 million and $0.9 million, respectively; and • Consulting and other selling expenses, which increased $0.1 million for both periods. General and administrative expense - General and administrative (“G&A”) expense includes executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expense decreased $0.1 million and increased $1.1 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • Compensation and benefits expenses, which increased $0.7 million and $1.7 million, respectively; • Outside consultant spend, which decreased $0.2 million for the three months ended February 28, 2025 and increased $1.1 million for the nine months ended February 28, 2025, compared to the three and nine months ended February 29, 2024, respectively; and • Depreciation and other corporate expenses, which decreased $0.5 million and $1.6 million, respectively. Three Months Ended Nine Months Ended (in thousands) Feb 28, 2025 Feb 29, 2024 $ Change Feb 28, 2025 Feb 29, 2024 $ Change Amortization of intangibles $ 2,598 $ 3,287 $ (689) $ 7,730 $ 10,474 $ (2,744) Goodwill impairment $ — $ 159,476 $ (159,476) $ — $ 159,476 $ (159,476) Change in fair value of contingent consideration $ 40 $ 112 $ (72) $ 272 $ 203 $ 69 Acquisition, restructuring and other items, net $ 3,286 $ 35,367 $ (32,081) $ 13,465 $ 44,767 $ (31,302) Other income, net $ 5,565 $ 156 $ 5,409 $ 6,244 $ 489 $ 5,755 Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company. • Amortization expense decreased $0.7 million and $2.7 million for the three and nine months ended February 28, 2025 compared to the three and nine months ended February 29, 2024, respectively, due to the intangible assets that were included in the divestiture of the dialysis, BioSentry, PICCs and Midlines businesses and the abandonment of the Syntrax product line. Goodwill impairment - Represents the impairment charge taken on goodwill. • The Company recorded a non-cash goodwill impairment charge of $159.5 million for the three and nine months ended February 29, 2024 as the fair value of the Med Tech reporting unit was less than its carrying value. Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration. • The change in the fair value for the three and nine months ended February 28, 2025 is related to the Eximo contingent consideration. Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items. 29 Table of Content Acquisition, restructuring and other item s, net, decreased by $32.1 million and $31.3 million for the three and nine months ended February 28, 2025, compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • Legal expense, related to litigation that is outside of the normal course of business, which decreased $23.3 million and $30.0 million, respectively, was driven by the $19.3 million settlement between the Company and BD in the prior year; • Mergers and acquisition expense, which decreased $0.1 million for the three months ended February 28, 2025 compared to the three months ended February 29, 2024 and increased $0.3 million for the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024; • Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024, which decreased $2.3 million for the three months ended February 28, 2025 compared to the three months ended February 29, 2024 and increased $5.7 million for the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024; • An impairment of $3.4 million on the Syntrax product technology intangible asset and an inventory write-off of $2.9 million was taken in the third quarter of fiscal year 2024 related to the abandonment of the Syntrax and RF product lines; • Transaction services agreements that were entered into as a result of the divestiture of the PICCs, Midline, dialysis and BioSentry businesses. The increase in the fees invoiced was $0.1 million and $0.8 million, respectively; • Manufacturing relocation expense related to the move of certain manufacturing lines from Queensbury, New York to a third party, which decreased $0.6 million for the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024; and • Other expense, mainly severance associated with organizational changes, which increased $0.3 million for the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. Other income, net - Other expenses include interest expense, foreign currency impacts and bank fees. Other income, net increased by $5.4 million and $5.8 million , for the three and nine months ended February 28, 2025, compared to the three and nine months ended February 29, 2024, respectively. The change for both periods was primarily driven by: • The Company achieved the sales milestone related to divested products in the third quarter of fiscal year 2025 and recorded a receivable of $5.5 million which will be paid to the Company in the fourth quarter of fiscal year 2025; • Unrealized foreign currency fluctuations, which increased $0.1 million and $0.3 million, respectively; and • Interest income, which decreased $0.2 million for the three months ended February 28, 2025 compared to the three months ended February 29, 2024. Income Tax Benefit Three Months Ended Nine Months Ended (in thousands) Feb 28, 2025 Feb 29, 2024 Feb 28, 2025 Feb 29, 2024 Income tax benefit (expense) $ (2) $ (12,004) $ 21 $ (6,597) Effective tax rate including discrete items — % 6.0 % (0.1) % 3.7 % Our effective tax rate including discrete items for the three months ended February 28, 2025 and February 29, 2024 was 0.0% and 6.0%, respectively. Our effective tax rate including discrete items for the nine months ended February 28, 2025 and February 29, 2024 was (0.1)% and 3.7%, respectively. In fiscal year 2025, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock-based compensation). Liquidity and Capital Resources We regularly review our liquidity and anticipated capital requirements and we believe that our current cash on hand provides sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. Our cash and cash equivalents totaled $44.8 million as of February 28, 2025, compared with $76.1 million as of May 31, 2024. As of February 28, 2025 and May 31, 2024 the Company did not have any outstanding debt. The fair value of contingent consideration liability as of February 28, 2025 and May 31, 2024, was $5.0 million and $4.7 million, respectively. 30 Table of Content The table below summarizes our cash flows: Nine Months Ended (in thousands) Feb 28, 2025 Feb 29, 2024 Cash provided by (used in): Operating activities $ (28,939) $ (33,159) Investing activities (7,555) 126,053 Financing activities 5,515 (59,248) Effect of exchange rate changes on cash and cash equivalents (317) 185 Net change in cash and cash equivalents $ (31,296) $ 33,831 During the nine months ended February 28, 2025 and February 29, 2024, cash flows consisted of the following: Cash used in operating activities Nine months ended February 28, 2025 and February 29, 2024: • Net loss of $27.9 million and $170.9 million, respectively, plus the non-cash items, primarily driven by depreciation and amortization and stock based compensation, along with the changes in working capital below, contributed to cash used in operations of $28.9 million and $33.2 million, respectively, for these periods. • For the period ended February 28, 2025, working capital was unfavorably impacted by decreased accounts payable, accrued liabilities and other liabilities of $18.5 million, along with increased accounts receivable, in ventory and prepaid expenses of $0.4 million, $2.5 million and $9.5 million, respectively. • For the period ended February 29, 2024, working capital was unfavorably impacted by increased inventory and prepaid expenses of $6.8 million and $7.6 million, respectively. This was offset by decreased accounts receivable of $2.3 million and increased accounts payable, accrued liabilities and other liabilities of $16.7 million. Cash (used in) provided by investing activities Nine months ended February 28, 2025 and February 29, 2024: • $3.7 million and $2.0 million, respectively, of cash was used for fixed asset additions; • $3.9 million and $3.2 million, respectively, of cash was used for Auryon placement and evaluation unit additions; • $100.0 million of cash was received for the divestiture of the dialysis and BioSentry businesses in the first quarter of fiscal year 2024; • $34.5 million of cash was received for the divestiture of the PICCs and Midline businesses in the third quarter of fiscal year 2024; and • $3.3 million of cash was used for the acquisition of exclusive licenses in the third quarter of fiscal year 2024. Cash provided by (used in) financing activities Nine months ended February 28, 2025 and February 29, 2024: • $6.3 million of proceeds from financing arrangements offset with $0.1 million of principal payments on the financing arrangements in the third quarter of fiscal year 2025; • $1.7 million of cash was used for the repurchase of commons shares in the first and second quarters of fiscal year 2025; • $50.0 million repayment of the Credit Agreement in connection with the completion of the dialysis and BioSentry divestiture in the first quarter of fiscal year 2024; • $10.0 million of contingent consideration payments made in the first quarter of fiscal year 2024; and • $0.9 million and $0.8 million, respectively, of proceeds from stock option and ESPP activity. On June 8, 2023 and in connection with the completion of the dialysis and BioSentry divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement, and as a result, the Credit Agreement was extinguished. Pursuant to the terms of the Credit Agreement, AngioDynamics had the option to repay this facility prior to the maturity date without penalty. We believe that our current cash balance, together with cash generated from operations will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make acquisitions of other businesses or technologies in the future for cash, we may require external financing. 31 Table of Content New Accounting Pronouncements Information regarding new accounting pronouncements is included in Note 16 to our consolidated financial statements in this Quarterly Report on Form 10-Q. 32 Table of Content